Screener
CorMedix CRMD Product sales, net — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by CorMedix in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: CorMedix’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 8:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001410098-26-000021
| Line item | For the Three Months Ended March 31, 2026 | For the Three Months Ended March 31, 2025 |
|---|---|---|
| Revenue: | ||
| Product sales, net | $121,916 | $39,082 |
| Contract revenue | 5,511 | - |
| Total Revenue | 127,427 | 39,082 |
| Cost of sales (exclusive of amortization of intangibles) | 12,005 | 1,545 |
| Amortization of intangibles | 10,300 | 52 |
| Gross profit | 105,122 | 37,485 |
| Operating Expenses: |
Item 1. Unaudited Condensed Consolidated Financial Statements.
FAQ
- What is CorMedix's product sales, net — total revenue?
- CorMedix (CRMD) reported product sales, net — total revenue of $121.92M in Q1 2026.
- How has CorMedix's product sales, net — total revenue changed year-over-year?
- CorMedix's product sales, net — total revenue increased by 211.9% year-over-year, from $39.08M to $121.92M.
- What does product sales, net — total revenue mean?
- This metric represents the total revenue generated from the commercial sale of pharmaceutical products after accounting for returns, allowances, and rebates. It serves as a primary indicator of market adoption and commercial success for the company's therapeutic portfolio. Tracking this figure allows investors to evaluate the growth trajectory and revenue-generating capacity of the company's core product offerings.
Ask your AI about CorMedix's product sales, net — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude